These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. Karussis DM, Vourka-Karussis U, Lehmann D, Ovadia H, Mizrachi-Koll R, Ben-Nun A, Abramsky O, Slavin S. J Clin Invest; 1993 Aug; 92(2):765-72. PubMed ID: 7688762 [Abstract] [Full Text] [Related]
5. Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. III. A role for anergy/deletion. Tan LJ, Vanderlugt CL, McRae BL, Miller SD. Autoimmunity; 1998 Aug; 27(1):13-28. PubMed ID: 9482204 [Abstract] [Full Text] [Related]
14. Specific immunoregulation of the induction and effector stages of relapsing EAE via neuroantigen-specific tolerance induction. Miller SD, Tan LJ, Kennedy MK, Dal Canto MC. Ann N Y Acad Sci; 1991 Dec 30; 636():79-94. PubMed ID: 1724364 [Abstract] [Full Text] [Related]
15. Successful treatment of paralytic relapses in adoptive experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance. Tan LJ, Kennedy MK, Dal Canto MC, Miller SD. J Immunol; 1991 Sep 15; 147(6):1797-802. PubMed ID: 1716280 [Abstract] [Full Text] [Related]
16. Acute immunosuppression and syngeneic bone marrow transplantation in ocular autoimmunity abort disease, but do not result in induction of long-term protection. Savion S, Silver PB, Chan CC, Caspi RR. Ocul Immunol Inflamm; 1998 Sep 15; 6(3):163-72. PubMed ID: 9785606 [Abstract] [Full Text] [Related]